Compare BROS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BROS | CORT |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 9.7B |
| IPO Year | 2021 | 2001 |
| Metric | BROS | CORT |
|---|---|---|
| Price | $41.88 | $111.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 5 |
| Target Price | $76.40 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 3.7M | 767.6K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.24 | N/A |
| EPS | ★ 0.41 | 0.09 |
| Revenue | ★ $1,638,159,000.00 | $761,407,000.00 |
| Revenue This Year | $27.34 | $26.08 |
| Revenue Next Year | $23.01 | $26.98 |
| P/E Ratio | ★ $102.71 | $1,231.33 |
| Revenue Growth | ★ 27.88 | 12.79 |
| 52 Week Low | $43.29 | $28.66 |
| 52 Week High | $74.02 | $126.38 |
| Indicator | BROS | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 26.89 | 47.35 |
| Support Level | N/A | $108.25 |
| Resistance Level | $59.07 | $124.30 |
| Average True Range (ATR) | 1.76 | 4.80 |
| MACD | -0.10 | -1.29 |
| Stochastic Oscillator | 2.21 | 16.70 |
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies, and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company-operated shops.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.